Mizuho Markets Cayman LP Grows Holdings in DexCom, Inc. $DXCM

Mizuho Markets Cayman LP increased its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 71.7% in the third quarter, Holdings Channel reports. The firm owned 127,093 shares of the medical device company’s stock after buying an additional 53,093 shares during the quarter. DexCom accounts for 0.3% of Mizuho Markets Cayman LP’s investment portfolio, making the stock its 23rd biggest holding. Mizuho Markets Cayman LP’s holdings in DexCom were worth $8,552,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. GAMMA Investing LLC increased its stake in DexCom by 2.5% in the third quarter. GAMMA Investing LLC now owns 7,043 shares of the medical device company’s stock valued at $474,000 after purchasing an additional 169 shares during the period. Inspire Investing LLC boosted its stake in shares of DexCom by 6.1% during the third quarter. Inspire Investing LLC now owns 3,139 shares of the medical device company’s stock worth $211,000 after buying an additional 180 shares during the period. Personal CFO Solutions LLC boosted its stake in shares of DexCom by 5.0% during the third quarter. Personal CFO Solutions LLC now owns 3,864 shares of the medical device company’s stock worth $260,000 after buying an additional 185 shares during the period. Inspire Advisors LLC grew its holdings in shares of DexCom by 2.5% during the third quarter. Inspire Advisors LLC now owns 7,926 shares of the medical device company’s stock worth $533,000 after buying an additional 194 shares during the last quarter. Finally, Integrated Wealth Concepts LLC grew its holdings in shares of DexCom by 6.3% during the first quarter. Integrated Wealth Concepts LLC now owns 3,329 shares of the medical device company’s stock worth $227,000 after buying an additional 196 shares during the last quarter. 97.75% of the stock is owned by hedge funds and other institutional investors.

DexCom Price Performance

DexCom stock opened at $66.34 on Tuesday. The company has a market cap of $25.53 billion, a P/E ratio of 31.59, a price-to-earnings-growth ratio of 1.25 and a beta of 1.48. DexCom, Inc. has a one year low of $54.11 and a one year high of $89.98. The business has a fifty day moving average of $70.63 and a two-hundred day moving average of $68.28. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.59 and a current ratio of 1.88.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Thursday, February 12th. The medical device company reported $0.68 earnings per share for the quarter, topping analysts’ consensus estimates of $0.65 by $0.03. The business had revenue of $1.26 billion for the quarter, compared to analysts’ expectations of $1.25 billion. DexCom had a net margin of 17.94% and a return on equity of 32.12%. During the same period in the prior year, the company posted $0.45 EPS. The business’s revenue for the quarter was up 13.1% on a year-over-year basis. As a group, analysts predict that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have commented on DXCM shares. BTIG Research reaffirmed a “buy” rating and set a $85.00 price objective on shares of DexCom in a research note on Monday, March 9th. Sanford C. Bernstein reiterated an “outperform” rating and issued a $86.00 target price (up from $84.00) on shares of DexCom in a research note on Friday, January 9th. Leerink Partners reissued an “outperform” rating and issued a $92.00 target price on shares of DexCom in a report on Tuesday, December 16th. Canaccord Genuity Group set a $95.00 price target on DexCom and gave the stock a “buy” rating in a report on Friday, February 13th. Finally, Robert W. Baird set a $87.00 price objective on shares of DexCom in a research report on Friday, February 13th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, DexCom has a consensus rating of “Moderate Buy” and an average price target of $85.50.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.